Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Yosuke MiyashitaRyo KoNaoko ShimadaYoichiro MitsuishiKeita MiuraNaohisa MatsumotoTetsuhiko AsaoTakehito ShukuyaRina ShibayamaRyo KoyamaKazuhisa TakahashiPublished in: Thoracic cancer (2020)
Additional mutations other than EGFR T790M may affect the efficacy of osimertinib treatment.